HUP0302003A2 - Il-8 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Il-8 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0302003A2
HUP0302003A2 HU0302003A HUP0302003A HUP0302003A2 HU P0302003 A2 HUP0302003 A2 HU P0302003A2 HU 0302003 A HU0302003 A HU 0302003A HU P0302003 A HUP0302003 A HU P0302003A HU P0302003 A2 HUP0302003 A2 HU P0302003A2
Authority
HU
Hungary
Prior art keywords
alkyl
heteroaryl
cr8r8
heterocyclyl
aryl
Prior art date
Application number
HU0302003A
Other languages
English (en)
Inventor
Qi Jin
Katherine L. Widdowson
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP0302003A2 publication Critical patent/HUP0302003A2/hu
Publication of HUP0302003A3 publication Critical patent/HUP0302003A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)

Abstract

A találmány (I) általános képletű vegyületekre - amelynek képletébenRb hidrogénatom, -NR6R7, hidroxi-, -ORa, alkil-, aril-, aralkil-,aril-alkenil-, cikloalkil-, cikloalkil-alkil-, heteroaril-,heteroaril-alkil-, heteroaril-alkenil-, heterociklil-, heterociklil-alkil- vagy heterociklil-alkenil-csoport, amelyek mindegyike adottesetben 1-3, szubsztituenst hordozhat; m, n és s értéke 1, 2 vagy 3,m' és t értéke 0, 1 vagy 2, q értéke 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 vagy10, R1 hidrogén-, halogénatom, nitro -, ciano-, alkil-, halogén-alkil-, alkenil-, alkoxi-, halogén-alkoxi-, azido-, -S(O)tR4, -(CR8R8)qS(O)tR4, hidroxi-, hidroxi-alkil-, aril-, aralkil-, aril-alkenil-, aril-oxi-, aril-alkoxi-, heteroaril-, heteroaril-alkil-,heteroaril-alkenil-, heteroaril-alkoxi-, heterociklil-, heterociklil-alkil-, heterociklil-alkoxi-, heterociklil-alkenil-, -(CR8R8)qNR4R5, -(CR8R8)qC(O)NR4R5, -(alkenil)-C(O)NR4R5, -(CR8R8)qC(O)-NR4R10, -S(O)3R8, -(CR8R8)qC(O)R11, -(alkenil)-C(O)R11, -(alkenil)-C(O)OR11, -(CR8R8)qC(O)OR11, -(CR8R8)qOC(O)R11 -(CR8R8)qNR4C(O)R11, -(CR8R8)qC(NR4)NR4R5, -(CR8R8)qNR4C(NR5)R11, -(CR8R8)qNHS(O)2R13, -(CR8R8)qS(O)2NR4R5 csoport; R4 és R5 hidrogénatom, adott esetbenszubsztituált alkil-, aril-, aralkil-, heteroaril-, heteroaril-alkil-,heterociklil-, heterociklil-alkil-csoport, vagy R4 és R5 anitrogénatommal együtt egy adott esetben további heteroatomottartalmazó ciklusos csoportot képez; R6 és R7 hidrogénatom vagy adottesetben szubsztituált alkil-, heteroaril-, arilcsoport, alkil-aril-,alkil-heteroalkilcsoport; vagy R6 és R7 a nitrogénatommal együtt egyadott esetben további heteroatomot tartalmazó és adott esetbenszubsztituált ciklusos csoportot képez. Y adott esetben egy vagy többR1 csoporttal szubsztituált furil-, tienil-, pirrolil-, oxazolil-,imidazolil-, tiazolil-, pirazolil-, izoxazolil-, izotiazolil-, 1,2,3-vagy 1,2,4-oxadiazolil-, 1,2,3- vagy 1,2,4-triazolil-, 1,2,3- vagy1,2,4-tiadiazolil-, piridil-, pirimidinil-, piridazinil-, pirazinil-,1,3,5- vagy 1,2,3- vagy 1,2,4-triazinil-, 1,2,4,5-tetrazinil-,indolil-, benzofuranil-, imidazolil-, benzimidazolil-, benzotiazolil-,kinolil-, izokinolil-, cinnolinil-, ftalazinil-, kinazolinil- vagykinoxalinilcsoport; R8 és R9 jelentése hidrogénatom vagy alkilcsoport;R10 -(alkil)-C(O)2R8 csoport, R11 hidrogénatom vagy adott esetbenszubsztituált alkil-, aril-, aralkil-, heteroaril-, heteroaril-alkil-,heterociklil- vagy heterociklil-alkil-csoport, és R13 alkil-, aril-,aril-alkil-, heteroaril-, heteroaril-alkil-, heterociklil- vagyheterociklil-alkil-csoport és gyógyászatilag elfogadható sóikra,valamint a vegyületeket tartalmazó, IL-8a vagy IL-8b receptorhozkötődő kemokin által mediált betegségek kezelésére szolgálógyógyszerkészítményekre vonatkozik. Ó
HU0302003A 2000-03-10 2001-03-09 Il-8 receptor antagonists and pharmaceutical compositions containing them HUP0302003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18841000P 2000-03-10 2000-03-10
PCT/US2001/007746 WO2001068568A2 (en) 2000-03-10 2001-03-09 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0302003A2 true HUP0302003A2 (hu) 2003-11-28
HUP0302003A3 HUP0302003A3 (en) 2005-06-28

Family

ID=22693024

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302003A HUP0302003A3 (en) 2000-03-10 2001-03-09 Il-8 receptor antagonists and pharmaceutical compositions containing them

Country Status (26)

Country Link
US (1) US6608077B2 (hu)
EP (1) EP1261336B1 (hu)
JP (1) JP2003535820A (hu)
KR (1) KR20020083174A (hu)
CN (1) CN1635979A (hu)
AR (1) AR030273A1 (hu)
AT (1) ATE353215T1 (hu)
AU (2) AU2001245606B2 (hu)
BR (1) BR0109002A (hu)
CA (1) CA2402891A1 (hu)
CO (1) CO5271660A1 (hu)
CY (1) CY1106514T1 (hu)
CZ (1) CZ20023007A3 (hu)
DE (1) DE60126480T2 (hu)
DK (1) DK1261336T3 (hu)
ES (1) ES2280350T3 (hu)
HU (1) HUP0302003A3 (hu)
IL (1) IL151431A0 (hu)
MX (1) MXPA02008818A (hu)
MY (1) MY133845A (hu)
NO (1) NO20024193L (hu)
NZ (1) NZ520912A (hu)
PL (1) PL363118A1 (hu)
PT (1) PT1261336E (hu)
WO (1) WO2001068568A2 (hu)
ZA (1) ZA200207216B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030689A1 (es) * 2000-03-14 2003-09-03 Smithkline Beecham Corp Compuestos de 3-aminosulfonil-2-hidroxifenil urea, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7056925B2 (en) 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
CA2547410C (en) * 2003-12-03 2013-07-30 Boehringer Ingelheim Pharmaceuticals, Inc. 1,2,3-triazole amide derivatives as inhibitors of cytokie production
WO2006043950A1 (en) * 2004-10-20 2006-04-27 Smithkline Beecham Corporation Il-8 receptor antagonists
EP2010180A4 (en) * 2006-04-21 2010-10-13 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
JP7092356B2 (ja) 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
WO2019137484A1 (zh) * 2018-01-11 2019-07-18 南京明德新药研发股份有限公司 Cxcr2拮抗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
TR199802694T2 (xx) * 1996-06-27 1999-03-22 Smithkline Beecham Corporation IL-8 resept�r kar��tlar�
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
PT1261336E (pt) 2007-03-30
AU2001245606B2 (en) 2006-03-09
MXPA02008818A (es) 2006-06-05
ZA200207216B (en) 2004-07-21
NO20024193D0 (no) 2002-09-03
CA2402891A1 (en) 2001-09-20
WO2001068568A3 (en) 2002-03-21
EP1261336A4 (en) 2004-12-15
CY1106514T1 (el) 2012-01-25
DK1261336T3 (da) 2007-06-04
AU4560601A (en) 2001-09-24
WO2001068568A2 (en) 2001-09-20
KR20020083174A (ko) 2002-11-01
ATE353215T1 (de) 2007-02-15
MY133845A (en) 2007-11-30
DE60126480D1 (de) 2007-03-22
NO20024193L (no) 2002-09-03
HUP0302003A3 (en) 2005-06-28
ES2280350T3 (es) 2007-09-16
US20030055286A1 (en) 2003-03-20
IL151431A0 (en) 2003-04-10
CO5271660A1 (es) 2003-04-30
DE60126480T2 (de) 2007-06-14
PL363118A1 (en) 2004-11-15
NZ520912A (en) 2005-02-25
AR030273A1 (es) 2003-08-20
JP2003535820A (ja) 2003-12-02
US6608077B2 (en) 2003-08-19
EP1261336A2 (en) 2002-12-04
CZ20023007A3 (cs) 2003-04-16
BR0109002A (pt) 2004-08-17
EP1261336B1 (en) 2007-02-07
CN1635979A (zh) 2005-07-06

Similar Documents

Publication Publication Date Title
HUP0302003A2 (hu) Il-8 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
HUP0001943A2 (hu) Benzimidazol- és benzotriazol-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0302382A2 (hu) IL-8 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
CA2243199C (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
Alborz et al. Synthesis and biological evaluation of some novel diastereoselective benzothiazole β-lactam conjugates
HUP0300599A2 (hu) Il-8 receptor antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303529A2 (hu) Új kinuklidin-karbamát-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0313790A (pt) Compostos de amida de ácido carboxìlico com efeito antagonista mch, medicamentos contendo estes compostos e processos para sua preparação
EA200401609A1 (ru) Лекарственное средство для лечения диабета
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
HUP0500096A2 (hu) Kondenzált heterociklusos vegyületek és analógjaik mint a nukleáris hormon receptor funkció modulátorai, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
ATE361924T1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
BRPI0606110A2 (pt) compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
BRPI0309309B8 (pt) antagonistas de receptor de trombina tricíclicos
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
HRP20090439T1 (hr) Supstituirani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
NO20061406L (no) Organiske forbindelser
HUP0104686A2 (hu) IL-8 receptor antagonista N-fenil-N'-(2-hidroxi-3-szulfamoil-fenil)-karbamid-származékok
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
HUP0103291A2 (hu) Eljárás citalopram előállítására
ATE289996T1 (de) Arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
Cusumano et al. 3-Hydroxy-1, 5-dihydro-2H-pyrrol-2-ones as novel antibacterial scaffolds against methicillin-resistant Staphylococcus aureus
RU2011102396A (ru) Аминосоединения и их медицинское применение

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished